Structural Heart

Older Patients and Asymptomatic Valvular Heart Disease

A new study out of the UK found that over a quarter of people aged 60+ have asymptomatic valvular heart disease, and revealed that prevalence increases as patients age — potentially providing new reasons to screen older patients for VHD.

  • VHD diagnosis generally involves echo exams, ordered in response to patient symptoms or abnormal cardiac auscultation.
  • However, this practice leaves many older patients with undetected VHD, raising interest in using echocardiography as a large-scale VHD screening tool.

To test that theory, researchers performed echo exams on 4,237 asymptomatic 60-and-over adults between 2007 and 2016, finding that…

  • A whopping 28.2% of participants had VHD
  • 2.4% of the VHD cases were clinically significant, including 94 moderate cases and 7 severe cases.
  • Significant VHD prevalence increased with age: 1.5% at 60-64yrs, 2.1% at 70-74yrs, 3.8% at 75-79yrs, and 10% at 85+.
  • The most common VHD cases were tricuspid (13.8%), mitral (12.8%), and aortic (8.3%) regurgitation.

Perhaps most actionable, age was the only factor associated with severe VHD (odds ratio: 1.07 per year), with the number of echo scans required to diagnose one clinically significant VHD case falling from 42 scans among 60-74yr olds to 15 scans among 75-and-over patients. 

Age-targeted VHD echo screening might result in even more positive cases in the real world, noting that only 8.6% of this study’s population was ≥80 years old, and other studies have found 51% prevalence of any VHD among over-65 patients and 17% prevalence of moderate-to-severe VHD among 80-and-over patients.

The Takeaway

By 2050 the over-60 population is expected to double, while the over-80 population triples. That elderly population surge will apparently come with a similar surge in undiagnosed VHD cases, unless there’s big changes to how we screen for VHD.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals January 5, 2026

Aficamten Approved, Enter a New HCM Contender January 5, 2026

After years of dedicated research and careful science, Cytokinetics’ aficamten (Myqorzo) is officially FDA approved for obstructive hypertrophic cardiomyopathy, marking the company’s first-ever regulatory approval and ending BMS mavacamten’s reign as the only oHCM treatment. The FDA’s decision stemmed from the SEQUOIA-HCM trial, which demonstrated aficamten’s efficacy over 24 weeks in symptomatic obstructive HCM patients […]

Cardiology Business December 18, 2025

Philips Acquires SpectraWAVE, Making Azurion Even Better December 18, 2025

After taking a two and a half year break since its last acquisition, Philips acquired SpectraWAVE for its HyperVue and X1-FFR technologies in a bid to extend its intravascular imaging lead. At the center of this acquisition, Philips’ Azurion is an image-guided therapy platform that already serves 7.6M patients annually. It combines coronary imaging and […]

Population Health December 14, 2025

Masters Athletes’ Hearts are Different, Especially When Imaged December 14, 2025

A recent JACC state-of-the-art review suggests that older athletes might face some unique cardiovascular changes, and although medical imaging can help identify their risk, the results need to be carefully interpreted. To better understand these patients, researchers looked at how physicians interpret multiple cardiac imaging modalities for masters athletes especially for changes in heart structure […]